These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 30790452)
1. Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on Senjo H; Kanaya M; Izumiyama K; Minauchi K; Hirata K; Mori A; Saito M; Tanaka M; Iijima H; Tsukamoto E; Itoh K; Ota S; Morioka M; Hashimoto D; Teshima T; Cancer Med; 2019 Mar; 8(3):953-962. PubMed ID: 30790452 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of metabolic tumour volume on baseline Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463 [TBL] [Abstract][Full Text] [Related]
3. Metabolic tumour area: a novel prognostic indicator based on Cui S; Xin W; Wang F; Shao X; Shao X; Niu R; Zhang F; Shi Y; Liu B; Gu W; Wang Y BMC Cancer; 2024 Jul; 24(1):895. PubMed ID: 39054508 [TBL] [Abstract][Full Text] [Related]
4. Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma. Decazes P; Becker S; Toledano MN; Vera P; Desbordes P; Jardin F; Tilly H; Gardin I Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1672-1679. PubMed ID: 29705879 [TBL] [Abstract][Full Text] [Related]
5. Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma. Cottereau AS; Lanic H; Mareschal S; Meignan M; Vera P; Tilly H; Jardin F; Becker S Clin Cancer Res; 2016 Aug; 22(15):3801-9. PubMed ID: 26936916 [TBL] [Abstract][Full Text] [Related]
6. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma. Toledano MN; Desbordes P; Banjar A; Gardin I; Vera P; Ruminy P; Jardin F; Tilly H; Becker S Eur J Nucl Med Mol Imaging; 2018 May; 45(5):680-688. PubMed ID: 29344718 [TBL] [Abstract][Full Text] [Related]
7. Value of Jiang C; Teng Y; Chen J; Wang Z; Zhou Z; Ding C; Xu J Ann Nucl Med; 2020 Dec; 34(12):911-919. PubMed ID: 33057996 [TBL] [Abstract][Full Text] [Related]
8. [ Xu HQ; Song LJ; Ding CY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1690-1700. PubMed ID: 38071047 [TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP. Umino K; Fujiwara SI; Minakata D; Yamamoto C; Meguro A; Matsuyama T; Sato K; Ohmine K; Izumi T; Muroi K; Kanda Y Leuk Lymphoma; 2019 Mar; 60(3):734-741. PubMed ID: 30188236 [TBL] [Abstract][Full Text] [Related]
11. A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [ Zhang X; Chen L; Jiang H; He X; Feng L; Ni M; Ma M; Wang J; Zhang T; Wu S; Zhou R; Jin C; Zhang K; Qian W; Chen Z; Zhuo C; Zhang H; Tian M Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1298-1310. PubMed ID: 34651227 [TBL] [Abstract][Full Text] [Related]
14. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma]. Ding CY; Guo Z; Sun J; Yang WP; Li TR Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362 [No Abstract] [Full Text] [Related]
15. Prognostic Values of Baseline Zhou Y; Zhang X; Qin H; Zhao Z; Li J; Zhang B; Sang S; Wu Y; Deng S Biomed Res Int; 2020; 2020():9746716. PubMed ID: 32185229 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma. Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875 [TBL] [Abstract][Full Text] [Related]
17. Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial. Girum KB; Cottereau AS; Vercellino L; Rebaud L; Clerc J; Casasnovas O; Morschhauser F; Thieblemont C; Buvat I J Nucl Med; 2024 Feb; 65(2):313-319. PubMed ID: 38071535 [TBL] [Abstract][Full Text] [Related]
18. Impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase on the clinical outcome of patients with diffuse large B-cell lymphoma. Umino K; Fujiwara SI; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y Leuk Lymphoma; 2019 Aug; 60(8):1926-1933. PubMed ID: 30947577 [TBL] [Abstract][Full Text] [Related]
19. Metabolic tumor burden on baseline Chen S; He K; Feng F; Wang S; Yin Y; Fu H; Wang H Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1830-1839. PubMed ID: 31187163 [TBL] [Abstract][Full Text] [Related]
20. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens. Goto N; Tsurumi H; Goto H; Shimomura YI; Kasahara S; Hara T; Yasuda I; Shimizu M; Murakami N; Yoshikawa T; Fukuno K; Takahashi T; Kito Y; Takami T; Moriwaki H Ann Hematol; 2012 May; 91(5):705-714. PubMed ID: 22183251 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]